medigraphic.com
ISSN 2070-8718 (Print)

2022, Number 1

Next >>

Rev Cub Gen 2022; 14 (1)

Relation of HLA-DRB1 alleles with therapeutic response in rheumatoid arthritis. A systematic review

Martínez TG

Language: Spanish
References: 24
Page: 1-15
PDF size: 536.68 Kb.


ABSTRACT

Introduction: The search for predictors of prognosis and therapeutic response in rheumatoid arthritis is essential to personalize therapy in these patients. Research on the contribution of the HLA-DRB1 allele may open up new opportunities to improve the diagnosis and therapy of the disease.
Objective: To describe recent studies that analyse the relationship of HLA-DRB1 alleles with the therapeutic response of rheumatoid arthritis patients treated with conventional or biological drugs.
Methods: A qualitative systematic review of the last ten years 2011-2021 was carried out in the Medline and Cochrane databases.
Results: The electronic search in Medline showed 200 articles. A total of 194 articles did not meet the inclusion criteria and were excluded, thus, 6 articles were included in the study. The electronic Cochrane search showed 25 articles and 23 were excluded, including only 2 articles matching the Medline search.
Conclusions: The HLA-DRB1 gene will be essential for the development of personalized diagnosis and treatment protocols in patients with rheumatoid arthritis. The studies included in this systematic review support the clinical therapeutic importance of the HLA-DRB1 alleles in positions 11, 70-74, as a biomarker of the therapeutic response of patients with rheumatoid arthritis.


REFERENCES

  1. Trouw L, Rispens T, Toes R. Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis. Nature Reviews/rheumatology. 2017;13:331-9. DOI: https://doi.org/10.1038/nrrheum.2017.15

  2. Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity 2017;46:183-96. DOI: https://10.1016/j.immuni.2017.02.006

  3. Fox, DA. Etiology of rheumatoid arthritis: A historical and evidence-based perspective. In: Chung KC, Clinical management of the rheumatoid hand, wrist, and elbow. Springer International Publishing: Suiza, 2016.13-9.

  4. Derksen VFAM, Huizinga TWJ, van der Woude D. The role of autoantibodies in the pathophysiologyof rheumatoid arthritis. V. Semin Immunopathol. 2017;39:437-46. DOI: https://10.1007/s00281-017-0627-z

  5. Bellucci E, Terenzi, La Paglia S, Gentileschi A, Tripoli C, Tani C et al. One year in review 2016: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2016 [acceso 29/03/2021];34:793-801. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27716458

  6. Wysocki T, Olesinska M, Paradowska-Gorycka A. Current Understanding of an Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritis–From Research to Clinical Practice. Cells. 2020;9:1127-58. DOI: https://10.3390/cells9051127

  7. Yarwood A, Huizinga T, Worthington J. The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA. Rheumatology. 2016;55:199-209. DOI: https://10.1093/rheumatology/keu323

  8. Mysler E, Caubet M, Lizarraga A. Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis. Open Access Rheumatol. 2021;13:139-52. DOI: https://10.2147/OARRR.S282627

  9. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M et al. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1). DOI: https://dx.doi.org/10.1186/2046-4053-4-1

  10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-8.

  11. Elson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38(6):727-35.

  12. Viatte S, Plant D, Han B, Fu B, Yarwood A, Thomson W et al. Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA. 2015;313(16):1645-56. DOI: https://10.1001/jama.2015.3435

  13. Jiang X, Askling J, Saevarsdottir S, Padyukov L, Alfredsson L, Viatte S, Frisell T. A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy - results from a Swedish cohort study. Arthritis Res Ther. 2016 18(1):288-98. DOI: https://10.1186/s13075-016-1174-z

  14. Burmester GR, Durez P, Shestakova G, Genovese MC, Schulze-Koops H, Li Y et al. Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. Rheumatology (Oxford), 2016;55(1):49-55. DOI: https://10.1093/rheumatology/kev258

  15. Oryoji K, Yoshida K, Kashiwado Y, Tanaka K, Mizuki SI, Tsukamoto H et al. Shared epitope positivity is related to efficacy of abatacept in rheumatoid arthritis. Ann Rheum Dis. 2018;77(8):1234-6. DOI: https://dx.doi.org/10.1136/annrheumdis-2017-211430

  16. Skapenko A, Smolen JS, Kavanaugh A, Arora V, Kupper H, Schulze-Koops H. Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate- or methotrexate-treated rheumatoid arthritis patients in OPTIMA. Clin Exp Rheumatol. 2019 [acceso 05/02/2021];37(5):783-90. DOI: https://pubmed.ncbi.nlm.nih.gov/30963994

  17. Gibson DS, McGeough CM, Watterson S, Blayney J, Wright GD, Pendleton A et al. Anti-tumour necrosis factor-alpha response associated with combined CD226 and HLA-DRB1[*]0404 haplotype in rheumatoid arthritis. Clin Exp Rheumatol;39(2):385-92. DOI: https://10.55563/clinexprheumatol/u1mi30

  18. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-77. DOI: https://10.1136/annrheumdis-2016-210715

  19. Bello AE, Perkins EL, Jay R, Efthimiou P. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatol. Res. Rev. 2017; 9,67–79. DOI: https://10.2147/OARRR.S131668

  20. Viatte S, Barton A. Genetics of rheumatoid arthritis susceptibility, severity, and treatment response. Semin Immunopathol. 2017;39:395-408. DOI: https://10.1007/s00281-017-0630-4

  21. Liu M, Degner J, Davis JW, Idler KB, Nader A, Mostafa NM et al. Identification of HLA-DRB1association to adalimumab immunogenicity. PLoS One. 2018;13(4). DOI: https://10.1371/journal.pone.0195325

  22. Nagafuchi Y, Shoda H, Sumitomo S, Nakachi S, Kato R, Tsuchida Y et al. Immunophenotyping of rheumatoid arthritis reveals a linkage between HLA-DRB1 genotype, CXCR4 expression on memory CD4(+) T cells, and disease activity. Sci. Rep. 2016;6:29338. DOI: https://10.1038/srep29338

  23. Ka S, Lee S, Hong J, Cho Y, Sung J, Kim HN et al. HLAscan: Genotyping of the HLA region using next-generation sequencing data. BMC Bioinform. 2017;18:258-66. DOI: https://10.1186/s12859-017-1671-3

  24. Bauer DC, Zadoorian A, Wilson LOW, Melbourne Genomics Health A, Thorne NP. Evaluation of computational programs to predict HLA genotypes from genomic sequencing data. Brief. Bioinform. 2018;19:179-87. DOI: https://10.1093/bib/bbw097




2020     |     www.medigraphic.com